Key result
Platelet signaling pathways promote colorectal cancer progression and represent promising targets to complement conventional treatments.
Why the study?
Conventional chemotherapy and radiotherapy for colorectal cancer have adverse effects that reduce adherence, prompting the investigation of platelet signaling pathways as alternative therapeutic targets.
Targeting platelet signaling pathways offers a potential therapeutic approach for colorectal cancer, though bleeding risks remain a significant challenge.
May support adjunctive platelet-targeted therapies in colorectal cancer; leaves open the need for trials addressing bleeding risks.
Colorectal cancer (CRC) is one of the most widespread tumor types, and it stands as the second leading cause of disease-related mortality globally. Due to its adverse effects, which lead to low patient adherence, new alternatives to conventional chemotherapy and radiotherapy treatments are being studied. Since, in most cases, platelets are positively involved in the persistence and progression of CRC, several elements of the platelet signaling pathway have been considered possible therapeutic targets. The present study assembles the main treatments for CRC and investigates the cellular mechanisms involved in the interaction between blood platelets and cancer cells. Additionally, this review cites other articles that propose possible therapeutic targets in the platelet activation pathways to be explored. Despite the reported benefits of antithrombotic therapy on CRC progression, some studies have warned about an increased bleeding risk and CRC incidence and highlight the importance of controlling this therapy through diagnostic tests. However, their high cost is still a significant obstacle to the population's access from low Human Development Index (HDI) countries. Many research groups have studied platelet signaling pathways in depth to develop a safer, more effective, and affordable therapy for the population.
No takes yet. Share an insight, caveat, or question.
Pedro Henrique Leite Bonfitto (2024) conducted a review in Colorectal cancer. Platelet signaling pathway inhibitors was evaluated. Platelet signaling pathways are actively involved in the persistence and progression of colorectal cancer, making them promising therapeutic targets to complement conventional treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: